SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (4346)5/20/1998 1:26:00 AM
From: Steve Fancy  Read Replies (1) of 6136
 
Well, here's another attempt at good news, Protease Inhibitor Prescription Data for the Week Ended 5/8/98. Market share based on the weekly data looks like it may be going up.

Please note that this data is presented differently then what I usually post. The percentage up or down is the PI market as a whole.

ú New protease inhibitor scrips were up 2.3% over the previous week's level. Agouron's market share of new protease inhibitor prescriptions was 33.5%, unchanged from 33.5% the previous week. For the first time, Agouron's market share in new protease inhibitors surpassed Merck's (which was 32.3% this week).

ú Total protease inhibitor scrips were up 1.3%, and Agouron's market share was 32.0%, up from 31.5% the week prior.

ú Refill protease inhibitor scrips were up 0.8% versus the previous week. Viracept's market share of refills was 31.2% for the week of May 8, up from 30.5% the previous week.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News